头孢曲松钠联合三联雾化治疗小儿支气管肺炎的临床效果  

Clinical efficacy of combined ceftriaxone sodium and triple nebulization therapy in children with bronchopneumonia

作　　者：尹利君 黄盼柳 YIN Lijun;HUANG Panliu(Wuming Hospital of Guangxi Medical University,Nanning 530100,China;不详)

机构地区：[1]广西医科大学附属武鸣医院,南宁市530100 [2]广西壮族自治区江滨医院,南宁市530000

出　　处：《临床合理用药》2025年第7期18-21,共4页Chinese Journal of Clinical Rational Drug Use

基　　金：广西卫生健康委自筹经费科研课题基金资助项目(Z20211094)。

摘　　要：目的观察头孢曲松钠联合三联雾化治疗小儿支气管肺炎的临床效果。方法选取2021年9月—2023年12月广西医科大学附属武鸣医院收治的支气管肺炎住院患儿300例,随机分为A、B、C 3组,每组100例。另选取同期健康体检儿童100名为对照组(D组)。A组予头孢曲松钠联合三联雾化治疗,B组单纯予三联雾化治疗,C组单纯予注射用头孢曲松钠治疗,用法用量同A组。3组均治疗1周后比较3组患儿临床症状体症(喘憋、发热、肺部湿啰音)缓解时间,治疗前后炎性因子[白细胞计数(WBC)、白介素-6(IL-6)、超敏C反应蛋白(hs-CRP)]水平变化及与D组的差异。结果A组喘憋、发热、肺部湿啰音等临床症状缓解时间均短于B组和C组(P<0.05);B组与C组临床症状缓解时间比较差异无统计学意义(P>0.05);治疗后,A、B及C组WBC、IL-6、hs-CRP水平均较治疗前下降(P<0.05)。A与D组WBC、IL-6、hs-CRP水平组间差异无统计学意义(P>0.05);A与B组、A与C组WBC、IL-6、hs-CRP水平比较A组更低且组间有统计学差异(P<0.05或P<0.01);B与C组WBC、IL-6、hs-CRP水平组间差异无统计学意义(P>0.05)。结论头孢曲松钠联合三联雾化治疗小儿支气管肺炎的临床效果肯定,可显著缩短临床症状持续时间,发挥明显抗炎作用。Objective To observe the clinical efficacy of combined ceftriaxone sodium and triple nebulization therapy in children with bronchopneumonia.Methods A total of 300 pediatric patients with bronchopneumonia admitted to Wuming Hospital of Guangxi Medical University from September 2021 to December 2023 were randomly divided into three groups(A,B and C)with 100 patients in each group.Additionally,100 healthy children who underwent physical examinations during the same period were selected as the control group(group D).Group A received combined therapy of ceftriaxone sodium and triple nebulization.Group B received triple nebulization alone.Group C received ceftriaxone sodium for injection alone,with the same dosage and administration as group A.The duration of symptom and signs relief(wheezing,fever and rales)were compared among the three groups after one week of treatment.Changes in inflammatory markers(WBC,IL-6 and hs-CRP)before and after treatment were also compared among the three groups and with the control group D.Results The duration of symptom and signs relief(wheezing,fever and rales)was significantly shorter in group A compared to group B and C(P<0.05).There was no significant difference in the duration of symptom relief between group B and C(P>0.05).After treatment,the levels of WBC,IL-6 and hs-CRP decreased significantly in group A,B and C compared to pretreatment levels(P<0.05).There was no significant difference in WBC,IL-6 and hs-CRP levels between group A and group D(P>0.05).However,group A had significantly lower levels of WBC,IL-6 and hs-CRP compared to group B and C(P<0.05 or P<0.01).There were no significant difference in WBC,IL-6 and hs-CRP levels between group B and C(P>0.05).Conclusion The combination of ceftriaxone sodium and triple nebulization are found to be a highly effective treatment for pediatric bronchopneumonia,resulting in a significant reduction in symptom duration and a marked anti-inflammatory response.

关 键 词：小儿支气管肺炎 头孢曲松钠 三联雾化 炎性因子 

分 类 号：R72[医药卫生—儿科]